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Available online at www.sciencedirect.comIn this review we discuss recent developments in psychiatric
genetics: on the one hand, studies using whole genome
approaches (genome-wide association studies (GWAS) and
exome sequencing) are coming close to finding genes and
molecular variants that contribute to disease susceptibility; on
the other candidate genes, such as the serotonin transporter,
continue to dominate in genetic studies of brain imaging
phenotypes and in protracted searches for gene by
environment interactions. These two areas intersect, in that
new information about genetic effects from whole genome
approaches, should (but does not always) inform the single
locus analyses.
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GWAS and exome sequencing
Whole genome approaches address the vexed question of
the genetic architecture of psychiatric disease: that is to
say, how many loci are involved, how common are the
variants, and what is the distribution of their effect sizes?
A very practical concern drives this seemingly arcane
question, namely, will it be possible to find genes in
which mutations are the main, if not the sole, predispos-
ing genetic cause? Finding even one such gene would
provide a starting point for investigating disease patho-
genesis because it is now relatively straightforward to
model highly penetrant alleles, whereas it is not clear how
to model a small effect locus that acts as part of a
polygenic system to exert its effect on a phenotype.
Using linear mixed models (an increasingly popular meth-
odology), Visscher and colleagues recently estimated the
proportion of variance in liability to schizophrenia attribu-
table to single nucleotide polymorphisms (SNPs) geno-
typed on commonly used arrays [1]. These SNPs are
chosen for typing because they are relatively common
Open access under CC BY license.www.sciencedirect.com (allele frequencies greater than 5%). The researchers were
able to put a lower limit on the genetic contribution: about
one-quarter of the variance in liability was explained by
common variants, refuting claims that common variants
have only a small role in the genetic cause of schizophrenia.
Conversely this means the remaining variation in suscepti-
bility could be attributable to rare variants.
Studies that have sequenced the exomes of patients with
schizophrenia and autism provide a bottom up answer to
the same question: rather than assessing the impact of
common variants, they search for rare coding variation.
Two studies of schizophrenia, one of 14 trios (two unaf-
fected parents and one affected child) [2], the other of 53
sporadic cases, 22 controls and their parents, both
reported de novo mutations in patients [3]. The smaller
study reported 4 non-sense mutations (out of a total of 15),
significantly higher than the expected rate, while the
larger study identified a ratio of 32 non-synonymous
mis-sense mutations to 2 synonymous mutations, again
significantly elevated over expectations.
Four papers recently reported exonic mutations in autism
[4,5,6,7]. Rates of non-sense mutations were elevated,
though only modestly so. More autism patients were
sequenced than in the schizophrenia studies, so an
important question was whether mutations ever occurred
in the same gene. This is a different question from that of
asking whether coding mutations are more common in
patients than controls. And it is an important question,
because finding recurrent mutations could lead to the
identification of a gene, or genes, causally implicated in
the disease. Taken together, in all three studies, 18 genes
with two functional mutations were found. However, by
chance about 12 genes would be expected to have more
than one mutation, and the enrichment was not quite
statistically significant (P = 0.063) [5].
Taking this observation further, Daly and colleagues
pointed out that the results are consistent with a poly-
genic model in which spontaneous coding mutations
increase risk between 5 and 20 fold [5]. This finding
is important because it demonstrates how the genetic
architecture of psychiatric disease consists of a conti-
nuum. As Visscher argues, the dichotomy of rare variant
of large effect versus common variant of small effect is
specious, since the frequency and effect size of the alleles
that increase susceptibility range across a continuum [8].
One important conclusion that emerges from both GWAS
and sequencing studies is that there are no common
variants of large effect. To be precise, common variantsCurrent Opinion in Neurobiology 2013, 23:57–61
58 Neurogeneticsthat increase the chance of disease 1.3 fold or more are
extremely unlikely to exist [9]. Similarly, for quantitative
phenotypes, the expected effect sizes are less than 0.5%
of phenotypic variance (for example, between 0.02 and
0.2% for each variant that contributes to variation in
height [10]).
Four papers reinforce the generality of this conclusion
[11,12,13,14]. All four deal with a field known as
imaging genetics, that is the study of association between
genetic variants and phenotypes obtained from structural
and functional imaging of the brain (almost all studies are
of human brains and the majority employ magnetic
resonance imaging modalities). An important conclusion
to emerge from these papers is that the genetic loci
influencing imaging genetic phenotypes ‘‘have compar-
able effect sizes to those observed in other genome-wide
association studies of complex traits’’ [11]. To take one
example, the rs10784502 marker is associated with 0.58%
of intracranial volume per risk allele [11]. The implica-
tions of this finding, and the other insights into the
genetic architecture of behavior we have discussed,
become clear when we turn to look at the second focus
of our review.
Candidate gene studies: brain imaging and
G  E
In this section we discuss developments in two areas, first
brain imaging and then gene by environment interactions
(G  E for short). For many years psychiatric geneticists
have had difficulties establishing robust associations be-
tween disease phenotype and allelic variant, leading some
to argue that it would be better to work with phenotypes
where the genetic architecture consists of loci of larger
effect. Proponents of this uncontroversial proposition
have suggested that neuroimaging phenotypes have the
requisite property: that genetic effects on brain structural
and functional variation are necessarily larger. The claim
is based on the assumption that some phenotypes (often
called endophenotypes) are biologically closer to the site
of genetic variation (measures of mRNA would be an
extreme example) and therefore the impact of genetic
variation must be larger. Thus one study of just twenty-
eight subjects reported an association between variation
in amygdala activation and variation in a length poly-
morphism of the serotonin transporter gene (5-
HTTLPR) [15]. The ‘short’ allele at this frequently
typed polymorphism has a frequency of about 30% in
European populations, and is thus a typical common
variant, whose effect size on complex phenotypes we
would expect to be small (explaining less than one
percent of the variation in a quantitative measure).
The short allele is reported to lower transcriptional ef-
ficacy (hence reduce levels of serotonin transporter
protein). To obtain the degree of significance reported
in the 2002 paper, the locus must explain about 28% of
phenotypic variance (95% confidence intervals 15–53%).Current Opinion in Neurobiology 2013, 23:57–61 This effect size is indeed much higher than anything
reported from genetic analyses of disease phenotypes, but
is it likely to be true? Given the results of the imaging
GWAS [11,12,13,14], the answer is that it is almost
certainly not.
This finding needs emphasizing since it contradicts the
results of a meta-analysis of the effect of a functional
Val158Met (rs4680) polymorphism in catechol-O-meth-
yltransferase (COMT) on neural endophenotypes [16].
That paper tested the hypothesis that ‘‘neural intermedi-
ate phenotypes are indeed more penetrant than beha-
vioral ones’’ and reported a significant association
between the COMT variant and test of ‘prefrontal acti-
vation’. The size of the effect was Cohen’s d = 0.73. For
those not familiar with this measure of effect size, it is the
approximately the same as 12% of the variance, much
larger than that found in the GWAS mentioned above.
Why the discrepancy? Is it really possible that many of the
studies are false positives? Now this hypothesis can be
tested, by determining whether the rate of positive find-
ings is consistent with the reported effect sizes [17]: in
other words, we can ask, given what the literature tells us
about the effect size, how many positive reports should
we expect to find? Ioannidis applied this test to structural
brain imaging findings and observed 142 statistically
significant findings among 461 studies, while the average
power of these studies indicated that we should expect
only 78.5 significant findings. This difference was itself
significantly different [18]. A recent meta-analysis inves-
tigating the effect of the serotonin transporter on amyg-
dala activation provides the necessary data to test for the
excess of false positives in imaging genetics studies [19].
Applying this, we find 11 statistically significant findings
when 5.5 are expected (P = 0.027).
We turn next to discuss developments in the field of gene
by environment interaction, focusing on publications
involving the serotonin transporter. For those unfamiliar
with this story, a brief reminder that the most highly cited
paper in neuroscience in 2003 was the observation from a
longitudinal study that possession of the ‘short’ allele of
the 5-HTTLPR only increased the risk of developing
depression in the presence of adverse life events [20].
This is an example of a gene by environment interaction
(G  E), which opened the door to detecting many more
such effects in studies that measured both environmental
and genetic predisposition. While quantitative genetic
studies indicated strongly that G  E existed in aggregate
[21], this was the first demonstration that it could be
detected at a single locus.
The hope was that studies of G  E, using carefully
phenotyped individuals, might yield robust results that
could be replicated. Unfortunately, the field has not
developed in this way. In the last few years threewww.sciencedirect.com
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they reach opposite conclusions: two found no evidence for
an interaction [22,23] while one concluded that there was
an effect [24]. The view taken by the authors of the positive
G  E meta-analysis is that the effect of G  E is broad:
‘‘rather than focus on a specific class of studies, we sought
to perform a meta-analysis on the entire body of work
assessing the relationship between 5-HTTLPR, stress,
and depression’’. In other words they incorporate more
environmental effects and outcomes than envisaged even
by the authors of the original study.
Additional findings over G  E at the serotonin transpor-
ter continue to accumulate, developing in two directions.
One is the incorporation of additional sequence variants
at the locus itself. Following the discovery that a single
nucleotide polymorphism within one of the long alleles of
the repeat means there is an ‘Lg’ allele with lower
transcriptional efficacy (functionally therefore behaving
like the ‘short’ allele) researchers now report G  E with
additional alleles. However, justification for testing these
additional alleles is weak. There has been no systematic
investigation of the variants that contribute to expression
variation in the transporter gene, but testing the effect of
55 SNPs distributed in a 100 kb window surrounding the
serotonin transporter locus, as well as the length poly-
morphism made two important observations [25]. First,
two SNPs in linkage disequilibrium explained 50% of
variation in transcript abundance; the 5-HTTLPR con-
tributed only 20%. Second, the Lg allele did not signifi-
cantly contribute to variation. Thus we still lack
comprehensive analysis of the relationship between func-
tional variants at the 5-HTTLPR locus and phenotypic
variation.
The second development is the increasing diversity of
phenotypes that are being tested: these include quality
of maternal parenting [26], affective state during marriage
[27], risky sexual behavior [28], childhood emotionality
[29], job satisfaction [30], perceived racial discrimination
[31], adult unresolved attachment [32], and gaze bias [33]. A
common feature of all these studies is the relatively small
sample size: all except one [30] use samples of less than a
thousand, and sometimes less than one hundred subjects
[32]. Given the now well established main effect sizes
discussed above, it seems unlikely, even allowing for the
large effects observed in an interaction analysis, that any of
these studies is sufficiently well powered to detect an effect.
The debate over G  E at the serotonin transporter locus
is now considerably polarized [34,35,36] but two recent
papers are worth highlighting. First, Duncan and Keller
used the pattern of publications to infer an excess of
positive findings in the G  E literature [37]. Their
argument is that publication bias can be detected as a
higher rate of positive results among novel findings com-
pared to replication attempts, since journals preferentiallywww.sciencedirect.com publish positive findings for a novel genetic association.
Second, one study replicated the design of the 2003
paper: a longitudinal study of a birth cohort of 1265
children born in New Zealand and studied from birth
to the age of 30 [38]. The authors point out that ‘‘both
studies have been conducted in the same geographic
region (the South Island of New Zealand) over a similar
historical period (1970–2010); both have gathered
repeated-measures data on multiple sources of stress
and adversity over the life course including: stressful life
events, child abuse and trauma, exposure to inter-parental
conflict, unemployment, violence victimisation and
similar measures; and both have gathered measures of
mental disorders using DSM criteria from adolescence
into adulthood.’’ After testing 13 stress measures and 4
outcomes for G  E effects between number of 5-
HTTLPR short alleles, the authors find ‘‘5 of the 52
results were statistically significant’’ (none become so if a
correction for multiple testing is taken into consideration)
but noted that ‘‘all significant tests of gene  environ-
environment interactions suggested that increasing num-
bers of ‘s’ alleles led to reduced sensitivity to stressful
events’’ (i.e. the opposite direction to that predicted from
the original study).
It is unlikely that either finding will dampen the enthu-
siasm for studies of G  E involving the serotonin trans-
porter. Panagiotou and Ioannidis recently reported that
the authors of primary studies are more likely to believe
that a strong association exists than methodologists (refer-
ring here to the authors of meta-analyses) [39]. Evidence
alone seems not be enough to change people’s minds. In a
careful presentation of the statistical difficulties inherent
in the detection of small effects, Gelman and Weakliem
[40] discuss what transpires when a theory can explain
findings in any direction. They quote Jeremy Freese who
describes this sort of argument as ‘‘more ‘vampirical’ than
‘empirical’—unable to be killed by mere evidence.’’
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